Corresponding Author: Jianming Tan, MD, PhD, Fuzhou General Hospital, Xiamen University, 156 Xi Er Huang Road, Fuzhou, Fujian 350025, P.R. China (tanjm156@yahoo.com.cn), and Camillo Ricordi, MD, Diabetes Research Institute and Cell Transplant Center, University of Miami, 1450 NW 10th Ave, Miami, FL 33136 (cricordi@med.miami.edu). Author Contributions: Drs Tan and Ricordi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Tan, Wu, Xu, Liao, Zheng, Pileggi, Ricordi. Acquisition of data: Tan, Wu, Liao, Sun, Chen, Yang, Cai, Gao. Analysis and interpretation of data: Tan, Wu, Xu, Liao, Zheng, Messinger, Pileggi, Ricordi. Drafting of the manuscript: Tan, Wu, Xu, Liao, Zheng, Messinger, Pileggi. Critical revision of the manuscript for important intellectual content: Tan, Wu, Xu, Liao, Zheng, Messinger, Sun, Chen, Yang, Cai, Gao, Pileggi, Ricordi. Statistical analysis: Tan, Wu, Xu, Liao, Zheng, Messinger, Pileggi. Obtained funding: Tan. Administrative, technical, or material support: Tan, Wu, Liao, Sun, Chen, Yang, Cai, Gao. The rest is here: Induction Therapy With Autologous Mesenchymal Stem Cells in Living ... … Continue reading →

Mesenchymal stem cells/marrow stromal cells (MSCs) present a promising tool for cell therapy, and are currently being tested in US FDA-approved clinical trials for myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease and autoimmune disorders. They have been extensively tested and proven effective in preclinical studies for these and many other disorders. There is currently a great deal of interest in the use of MSCs to treat neurodegenerative diseases, in particular for those that are fatal and difficult to treat, such as Huntington's disease and amyotrophic lateral sclerosis. Proposed regenerative approaches to neurological diseases using MSCs include cell therapies in which cells are delivered via intracerebral or intrathecal injection. Upon transplantation into the brain, MSCs promote endogenous neuronal growth, decrease apoptosis, reduce levels of free radicals, encourage synaptic connection from damaged neurons and regulate inflammation, primarily through paracrine actions. MSCs transplanted into the brain have been demonstrated to promote functional recovery by producing trophic factors that induce survival and regeneration of host neurons. Therapies will capitalize on the innate trophic support from MSCs or on augmented growth factor support, such as delivering brain-derived neurotrophic factor or glial-derived neurotrophic factor into the brain to support injured neurons, using genetically engineered … Continue reading →

stem cell therapy, stem cell treatment, stem cell transplants, stem cell facelift, stem cell arthritis, stem cell and autism, stem cell and multiple sclerosis, arthritis pain and stem cell, knee pain and stem cell, stem cell treatment autoimmune, Mesenchymal Stem Cells Therapy, Platelet Rich Plasma (PRP) Injections CELL THERAPY FLORIDA with newer techniques and equipment, can easily obtain from a patient, activate, and transplant adult stem cells back to the patient by a simple office procedure done within the same day as part of the Stem Cell USA Program. The process of actively extracting, concentrating and administering these stem cells has been shown in clinical trials to have beneficial effects in degenerative and other conditions. Once injected, stem cells follow inflammatory signals from damaged tissues and have multiple ways of repairing these damaged areas. Studies have also shown that these are capable of homing to and secrete proteins and peptides that stimulate healing of damaged tissue. Adult stem cells isolated from fat tissue have the ability to become different cell types (i.e. nerve cells, liver cells, heart cells, and cartilage cells). 1. Harvesting: CELLMedix can collect adult stem cells from multiple sites of the body. For our Stem Cell USA … Continue reading →

The Centeno-Schultz Clinic is a research-based medical practice founded by Christopher J. Centeno,M.D., and John R. Schultz, M.D. . The Regenexx procedures have been studied extensively for several years and we maintain what we believe to be the worlds largest human mesenchymal stem cell re-implantation database for orthopedic purposes. The original Regenexx-C procedure was first used as part of an IRB supervised clinical trial from 2005-2007. During this time our medical practice invested hundreds of thousands of dollars in providinginvestigationalcare, with all patientsreceivingbefore and after research-grade MRIs. For more information on how physicians innovate versus how FDA/drugcompaniesdiscover new drugs, see this link. By late 2007, once the physicians were satisfied that the procedure was working and that the complications were less than existing surgical care, the clinic began treating patients. Since that time the clinic has published many medical research papers listed in the U.S. Library of Medicine (see this link for an incomplete list). Every patient treated by us is entered into a treatment registry and will be contacted atvarioustime points regarding the outcome of the procedure, any complications, etc As a result, we have extensive experience in what works and what doesnt work. In addition, based onourpublished complications … Continue reading →